Oxolife, la biotecnológica enfocada a tratar la infertilidad femenina, y el grupo de Balance Energético, Pubertad y Salud Reproductiva, de la Universidad de Córdoba han establecido una colaboració...
The SARS-CoV-2 pandemic that is hitting many countries has clearly affected the medical start-up and spin-off ecosystem. After talking to some of the companies we support we have seen that it has not ...
The biotech company Oxolife, created to develop a new treatment to improve the female fertility rate, completed its first funding round by raising 5,000,000 euros in an investment led by Inveready Ass...
Agnès Arbat and Ignasi Canals lead Oxolife, a startup that is developing OXO-001, a drug with the potential to treat female infertility as it increases the chances of embryo implantation a 65%. Arba...
Agnès Arbat y Ignasi Canals lideran Oxolife, una startup que desarrolla OXO-001, un fármaco con el potencial de tratar la infertilidad femenina al incrementar en un 65% la implantación embrionar...